Ilia I. Ouspenski

Array ( [id] => 11866191 [patent_doc_number] => 20170233476 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'Antibody Therapeutics That Bind CTLA4' [patent_app_type] => utility [patent_app_number] => 15/043269 [patent_app_country] => US [patent_app_date] => 2016-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 26548 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15043269 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11053360 [patent_doc_number] => 20160250322 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-01 [patent_title] => 'VECTOR CO-EXPRESSING VACCINE AND COSTIMULATORY MOLECULES' [patent_app_type] => utility [patent_app_number] => 15/016375 [patent_app_country] => US [patent_app_date] => 2016-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 26871 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15016375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11025164 [patent_doc_number] => 20160222119 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-04 [patent_title] => 'ISOLATED B7-H4 SPECIFIC COMPOSITIONS AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 15/009082 [patent_app_country] => US [patent_app_date] => 2016-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 34153 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15009082 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11018106 [patent_doc_number] => 20160215059 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-28 [patent_title] => 'ICOS BINDING PROTEINS' [patent_app_type] => utility [patent_app_number] => 15/006560 [patent_app_country] => US [patent_app_date] => 2016-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 51483 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15006560 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11784024 [patent_doc_number] => 09393301 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-07-19 [patent_title] => 'Immunopotentiative composition' [patent_app_type] => utility [patent_app_number] => 15/000863 [patent_app_country] => US [patent_app_date] => 2016-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 32 [patent_no_of_words] => 14068 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15000863 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11210945 [patent_doc_number] => 09439962 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-09-13 [patent_title] => 'Immunopotentiative composition' [patent_app_type] => utility [patent_app_number] => 15/000869 [patent_app_country] => US [patent_app_date] => 2016-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 32 [patent_no_of_words] => 14075 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15000869 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10799188 [patent_doc_number] => 20160145345 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-26 [patent_title] => 'Human Anti-B7RP1 Neutralizing Antibodies' [patent_app_type] => utility [patent_app_number] => 14/995983 [patent_app_country] => US [patent_app_date] => 2016-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 25934 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14995983 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14145477 [patent_doc_number] => 10253097 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-09 [patent_title] => Isolated antibody [patent_app_type] => utility [patent_app_number] => 14/988938 [patent_app_country] => US [patent_app_date] => 2016-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 43 [patent_no_of_words] => 22761 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 160 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14988938 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11054475 [patent_doc_number] => 20160251436 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-01 [patent_title] => 'Anti-PD-1 Antibodies' [patent_app_type] => utility [patent_app_number] => 14/975769 [patent_app_country] => US [patent_app_date] => 2015-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 20117 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 20 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14975769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12118836 [patent_doc_number] => 20180002422 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'METHODS FOR UPREGULATING IMMUNE RESPONSES USING COMBINATIONS OF ANTI-RGMb AND ANTI-PD-1 AGENTS' [patent_app_type] => utility [patent_app_number] => 15/533532 [patent_app_country] => US [patent_app_date] => 2015-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 52969 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15533532 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10813767 [patent_doc_number] => 20160159927 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-09 [patent_title] => 'IDENTIFICATION OF VSIG8 AS THE PUTATIVE VISTA RECEPTOR (V-R) AND USE THEREOF TO PRODUCE VISTA/VSIG8 AGONISTS AND ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 14/960973 [patent_app_country] => US [patent_app_date] => 2015-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 95182 [patent_no_of_claims] => 51 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14960973 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10813745 [patent_doc_number] => 20160159905 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-09 [patent_title] => 'ANTI-PD-1 ANTIBODIES AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/958053 [patent_app_country] => US [patent_app_date] => 2015-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 55062 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14958053 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11785020 [patent_doc_number] => 09394365 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2016-07-19 [patent_title] => 'Reducing systemic regulatory T cell levels or activity for treatment of alzheimer\'s disease' [patent_app_type] => utility [patent_app_number] => 14/957065 [patent_app_country] => US [patent_app_date] => 2015-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 56 [patent_no_of_words] => 21366 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14957065 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13106899 [patent_doc_number] => 10072082 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-09-11 [patent_title] => Cancer immunotherapy by disrupting PD-1/PD-L1 signaling [patent_app_type] => utility [patent_app_number] => 14/950748 [patent_app_country] => US [patent_app_date] => 2015-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 39748 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 222 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14950748 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13106897 [patent_doc_number] => 10072081 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-09-11 [patent_title] => Anti-CTLA4, anti-GLUT2 protein for the treatment of type 1 diabetes [patent_app_type] => utility [patent_app_number] => 14/943852 [patent_app_country] => US [patent_app_date] => 2015-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 23111 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14943852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10822083 [patent_doc_number] => 20160168248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-16 [patent_title] => 'Regulatory T Cell Mediator Proteins and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 14/940940 [patent_app_country] => US [patent_app_date] => 2015-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 49326 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14940940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11205166 [patent_doc_number] => 09434785 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2016-09-06 [patent_title] => 'Anti-human OX40L antibodies and methods of treating graft versus host disease with the same' [patent_app_type] => utility [patent_app_number] => 14/935937 [patent_app_country] => US [patent_app_date] => 2015-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 16 [patent_no_of_words] => 86443 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14935937 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11415271 [patent_doc_number] => 09562087 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-02-07 [patent_title] => 'High affinity PD-1 agents and methods of use' [patent_app_type] => utility [patent_app_number] => 14/931725 [patent_app_country] => US [patent_app_date] => 2015-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 52 [patent_no_of_words] => 45235 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14931725 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15784939 [patent_doc_number] => 10626176 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-21 [patent_title] => Methods of treating conditions with antibodies that bind B7-H4 [patent_app_type] => utility [patent_app_number] => 15/522061 [patent_app_country] => US [patent_app_date] => 2015-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 26 [patent_no_of_words] => 30334 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15522061 [rel_patent_id] =>[rel_patent_doc_number] =>)